Antidote for overdoses of gemcitabine is unknown. When a single dose as high as 5700 mg/m2 was administered by I.V. infusion over 30 minutes every 2 weeks to several patients in a Phase 1 study the principle toxicities seen were myelosuppression, paresthesia and severe rash. Monitoring of appropriate blood counts and supportive therapy for patient, as necessary should be given if overdose is suspected.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
